Celladon Corporation to Present at 11th Global Cardio

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Celladon Corporation to Present at 11th Global Cardio Vascular Clinical Trial Forum

SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq: CLDN ), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Janice Pogoda, Ph.D., Executive Director of Biostatistics at Celladon, has been selected to present guidance for future clinical trials of therapies for cardiac disease during the 11 th Global Cardio Vascular Clinical Trial Forum (CVCT). The presentation will take place during Session 1: The Specific Framework of Cell and Gene Therapy Trials, on Saturday, December 6, 2014 from 11:30 a.m. – 3:00 p.m. EST in Washington D.C.

"We are honored that Janice has been selected to speak at the prestigious CVCT forum and believe it is a testament to our leadership in cardiovascular disease," said Krisztina Zsebo, Chief Executive Officer of Celladon. "Ongoing research and development is critical to ensure we are bringing the best therapies possible to patients and we are proud to support the efforts of CVCT."

The CVCT Forum brings together key decision makers, clinical trial specialists, methodologists, investigators, regulatory authorities and industry R&D experts to discuss trial design, conduct, interpretation, approval and implementation to support the development of next generation therapies and devices for cardiovascular disease.

About Celladon

Celladon is a clinical-stage biotechnology company applying its leadership position in the field of cardiovascular gene therapy to develop novel therapies for diseases with tremendous unmet medical needs. Our lead programs target SERCA enzymes which are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, vascular disease, diabetes and neurodegenerative diseases. MYDICAR, the Company's most advanced product candidate, uses gene therapy to target SERCA2a, which is an enzyme that becomes deficient in patients with advanced heart failure. Celladon has completed enrollment of a 250 patient Phase 2b clinical trial evaluating the efficacy of MYDICAR in reducing the frequency of, or delaying heart failure-related hospitalizations. This randomized, double-blind, placebo-controlled, multinational trial is evaluating a single intracoronary infusion of MYDICAR versus placebo added to a maximal, optimized heart failure regimen in patients with New York Heart Association class III or IV symptoms of chronic heart failure due to systolic dysfunction. The Company has received Breakthrough Therapy designation from the FDA for this MYDICAR program and expects to report results from the Phase 2b clinical trial in April 2015. In addition, the Company conducts research and development on its mSCF gene therapy program for cardiac diseases. Celladon has also identified a number of potential first-in-class compounds addressing novel targets in diabetes and neurodegenerative diseases with its small molecule platform of SERCA2b modulators. For more information, please visit www.celladon.com .

Forward-Looking Statements –

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Celladon's plans to research, develop and commercialize product candidates, as well as expected timing for reporting results from clinical trials.   Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Celladon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the process of conducting product development activities and clinical trials and obtaining regulatory approval to commercialize product candidates, our reliance on third parties, the need to raise additional funding when needed in order to conduct our business, and the degree of market acceptance of MYDICAR by physicians, patients, third-party payors and others in the medical community. These and other risks and uncertainties are described more fully in Celladon's filings with the Securities and Exchange Commission, including without limitation its Form 10-Q for the quarter ended September 30, 2014. All forward-looking statements contained in this press release speak only as of the date on which they were made. Celladon undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

For further information, please contact: Fredrik Wiklund Vice President, Corporate Development and Investor Relations +1- 858-432-7215

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 68

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Broadridge Brings Boyman In to Sharpen Its Market Story

Updated Category News Views 66

Financial plumbing rarely gets applause, which is precisely why Broadridge needs somebody who can explain its value without turning the pitch into alphabet soup. Lauren Boyman arrives as chief marketing and communications officer on November 23, taking charge of global marketing, corporate communications, product positioning, digital strategy, lead generation and thought...

Continue Reading
Frontline Claims Survey Tests AI's Real Desk Impact

Updated Category News Views 45

Claims software can look brilliant in a conference-room demo and still create a fresh pile of headaches for the person handling a real injured worker’s file. That is why the 2026 Workers’ Compensation Benchmarking Study opening its survey to frontline claims professionals matters more than the usual industry questionnaire. This is an operating-reality check, not just...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 14

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Trucking Hub Bets on Faster MVR Checks Nationwide Today

Updated Category News Views 38

Driver paperwork is where plenty of supposedly modern fleet systems still go to die. Trucking Hub’s Nov. 18 launch of GetMVR.com takes a clean swing at that mess: an online platform for ordering Motor Vehicle Records in all 50 states, with instant reports available in 48. It is not glamorous software, and frankly that is why it may matter. Fleets do not lose sleep over...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 180

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
Navan’s Travel Survey Sells Friction as a Business Case

Updated Category News Views 167

A forgotten charger can turn a routine trip into a small mutiny. That is the useful little truth sitting underneath Navan’s new survey of 2,000 Americans who travel for leisure or business. The company is poking at the annoyances people carry from the bedroom packing pile to the jet bridge: forgotten items, rushed airport arrivals, pre-flight drinks, chatty strangers,...

Continue Reading
Health In Tech Brings a Tech Veteran Onto Its Board

Updated Category News Views 31

Board appointments rarely make the cash register ring, but they can tell you where management thinks the next bruises are coming from. Health In Tech has added Tim Cortes as an independent director, put him in charge of the Compensation Committee, and placed him on both the Audit and Nominating and Corporate Governance Committees. For an AI-enabled insurance technology...

Continue Reading
De Beers Puts Namibia's 176-Carat Owishi on Display

Updated Category News Views 54

A 176-carat natural diamond can still make a room stop breathing, even in a trade battered by arguments over lab-grown supply, luxury spending, and what “rare” ought to mean anymore. De Beers Group, working with Grandview Klein Diamond, has unveiled Namibia’s Owishi natural diamond in Washington, DC. That is the hard fact on the table: a large Namibian stone, a U.S....

Continue Reading
Katahdin's Portland Branch Bet Moves Downtown in 2027

Updated Category News Views 0

Exchange Street is getting a real-world vote of confidence, and that is more interesting than another app update ever will be. Katahdin Trust intends to open a full-service branch at 120 Exchange Street in downtown Portland, with renovations slated to begin early in 2027 and an opening expected later that year. For a Maine community bank with nearly $1.2 billion in...

Continue Reading

Top 5 Most Recently Viewed Articles

Cohen & Steers to Release Q2 2026 Results Soon

Updated Category News Views 30

Mark Your Calendars: July 16 Q2 2026 Results There's a buzz in the air, folks. Cohen & Steers, Inc. (NYSE: CNS) is gearing up to release its second-quarter results for 2026 on July 16, right after the market bell tolls. Now, for those in the know, the earnings release is less about the numbers dropping and more about the story they tell. On the next day, July 17, their...

Continue Reading
Legal Notice for Skye Bioscience and Perrigo Investors Amid Lawsuits

Updated Category News Views 236

Overview of Ongoing Legal Matters for Investors Bragar Eagel & Squire, P.C., a prominent law firm specializing in investor rights, wishes to inform shareholders about class action lawsuits that have been initiated against Skye Bioscience, Inc. (NASDAQ: SKYE) and Perrigo Company plc (NYSE: PRGO). These lawsuits present a vital opportunity for investors to advocate for...

Continue Reading
JD.com Shares Insights on Upcoming Financial Releases

Updated Category News Views 136

JD.com Announces Upcoming Financial Report JD.com, Inc. (NASDAQ: JD) is gearing up to release its unaudited financial results for the fourth quarter and full year of 2024. This significant announcement is scheduled for March 6, 2025, and will provide investors with a detailed look into the company's performance. Conference Call Details As part of this release, JD.com's...

Continue Reading
Marketing Maven Public Relations Celebrated for Industry Disruption

Updated Category News Views 146

Marketing Maven Public Relations and Its Notable Recognition Marketing Maven Public Relations has truly made a mark in the public relations and marketing landscape, earning recognition as a nominee for the prestigious Disruptors Awards. This accolade celebrates organizations that pioneer innovative strategies, demonstrate strategic leadership, and make impactful changes...

Continue Reading
OneMedNet Unveils Groundbreaking Platform Advancements

Updated Category News Views 132

Introduction to OneMedNet's Innovative Platform OneMedNet Corporation, a notable player in the healthcare technology field, is gearing up to showcase a groundbreaking data exploration platform at RSNA 2025. This platform, which has received enthusiastic validation from clients and industry experts, marks a significant leap in how healthcare entities manage and analyze...

Continue Reading